Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy
- Conditions
- Interventions
- First Posted Date
- 2007-11-21
- Last Posted Date
- 2016-09-30
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 2
- Registration Number
- NCT00561834
- Locations
- 🇺🇸
Rocky Mountain Lions Eye Institute, Aurora, Colorado, United States
Prevention of Vision Loss in Patients With Age-Related Macular Degeneration (AMD) by Intravitreal Injection of Bevacizumab and Ranibizumab
- Conditions
- Interventions
- First Posted Date
- 2007-11-16
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- Klinikum Bremen-Mitte, gGmbH
- Target Recruit Count
- 366
- Registration Number
- NCT00559715
- Locations
- 🇩🇪
Department of Pharmacology at Klinikum Bremen Mitte, Bremen, Germany
Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (CARBON)
- Conditions
- Interventions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- OPKO Health, Inc.
- Registration Number
- NCT00557791
Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis
- Conditions
- Interventions
- First Posted Date
- 2007-10-19
- Last Posted Date
- 2009-04-16
- Lead Sponsor
- Barnes Retina Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00546936
- Locations
- 🇺🇸
Barnes Retina Institute, St. Louis, Missouri, United States
🇺🇸Macula-Retina-Vitreous Service, Midwest Eye Institute, Indianapolis, Indiana, United States
Bevacizumab Versus Ranibizumab for Diabetic Retinopathy
- Conditions
- Interventions
- First Posted Date
- 2007-10-17
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- Ursula Schmidt-Erfurth, M.D.
- Target Recruit Count
- 30
- Registration Number
- NCT00545870
- Locations
- 🇦🇹
Department of Ophthalmology, Medical University of Vienna, Vienna, Austria
Intravitreal Ranibizumab for the Prevention of Radiation Maculopathy Following Plaque Radiotherapy
- Conditions
- First Posted Date
- 2007-10-08
- Last Posted Date
- 2007-10-08
- Lead Sponsor
- Shields, Shields and Associates
- Target Recruit Count
- 400
- Registration Number
- NCT00540930
- Locations
- 🇺🇸
Wills Eye Institute, Philadelphia, Pennsylvania, United States
Changes in Retinal Function After Intravitreal Ranibizumab for Age-related Macular Degeneration
- Conditions
- First Posted Date
- 2007-10-04
- Last Posted Date
- 2011-04-15
- Lead Sponsor
- Prince of Songkla University
- Target Recruit Count
- 25
- Registration Number
- NCT00539734
- Locations
- 🇹🇭
Department of Ophthalmology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand
Evaluation of Dosing Interval of Higher Doses of Ranibizumab
- Conditions
- Interventions
- First Posted Date
- 2007-09-21
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Brandon G. Busbee, MD
- Target Recruit Count
- 37
- Registration Number
- NCT00533520
- Locations
- 🇺🇸
Tennessee Retina, P.C., Nashville, Tennessee, United States
Ranibizumab and Reduced Fluence PDT for AMD
- First Posted Date
- 2007-09-11
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Texas Retina Associates
- Target Recruit Count
- 60
- Registration Number
- NCT00527475
- Locations
- 🇺🇸
California Retina Consultants & Research Foundation, Santa Barbara, California, United States
🇺🇸Associated Retinal Consultants, Ann Arbor, Michigan, United States
🇺🇸Texas Retina Associates, Arlington, Texas, United States
Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2016-03-04
- Lead Sponsor
- Novartis
- Target Recruit Count
- 234
- Registration Number
- NCT00504959
- Locations
- 🇹🇷
Novartis Investigative SIte, Ankara, Turkey
🇦🇺Novartis Investigational Site, Melbourne, Australia
🇬🇧Novartis Investigative Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.